Please Wait.....
Report
Cancer Biomarkers Market Assessment, By Type [Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers], By Technology [OMICS, Imaging Technology, Immunoassays, Cytogenetics, Bioinformatics, Others], By Cancer Type [Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Blood Cancer, Prostate Cancer, Ovarian Cancer, Stomach Cancer, Liver Cancer, Other Cancer], By Application [Diagnostics, Research and Development, Prognostics, Risk Assessment, Treatment, Other Applications], By End-user [Hospitals, Pharmaceutical and Biotechnological Companies, Diagnostic Laboratories, Cancer Research Institutes, Others], By Region, Opportunities and Forecast, 2017-2031F
Market Report I 2024-04-19 I 224 Pages I Market Xcel - Markets and Data
Global cancer biomarkers market size was valued at USD 15.1 billion in 2023, which is expected to reach USD 43.53 billion in 2031, with a CAGR of 14.15% for the forecast period between 2024 and 2031F. The global cancer biomarkers market is expected to grow due to the growing research environment around cancer biomarkers. Cancer biomarkers are a highly effective way of cancer detection as they offer precision diagnostics, since various market players are researching to find more effective and precise cancer biomarkers.
The number of cancer cases has significantly increased in recent years due to factors like genetic mutations, changing lifestyles, smoking, and alcohol consumption. Increasing cancer cases demand more precise and rapid screening methods, which foster market growth. The growing prevalence of cancer patients coupled with cutting-edge technologies is expected to fuel market growth. Factors such as the increasing prevalence of cancer patients, government initiatives, regulatory policies, and technological advancements are expected to fuel market growth.
In July 2023, Quest Diagnostics, the leading provider of diagnostic information services, announced the launch of a novel prostate cancer biomarker test through its subspecialty pathology business, AmeriPath, in collaboration with Envision Sciences. The new, tissue-based test service is intended to address the pressing clinical need for tests to help identify and differentiate potentially aggressive cases of prostate cancer in men. Such cutting-edge product approvals are expected to play a significant role in driving the global cancer biomarkers market.
Increasing Research and Development in Cancer Biomarkers
Cancer is one of the leading causes of death globally, without any exception in developed or developing countries. Cancer biomarkers have been significant contributors to cancer screening. Research institutes and market players are consistently involved in cancer biomarker research which is being supported by government authorities, investors, and regulatory bodies. Research is mainly focused on the identification, optimization, and utilization of different biomarkers to facilitate cancer diagnosis, research, and treatment. Thus, increasing investment by the government in research and development along with companies working in cancer biomarkers space are expected to fuel market growth.
In April 2023, a team led by Florida State University chemists developed a new test for detecting biological markers related to several types of cancer. The sensing platform is made of a gold nanoparticle and molecules called peptides that are labeled with a dye. Chemical bonds connect the components, while the gold nanoparticle restrains the dye from glowing in the presence of UV light. When a patient sample containing Enzyme MMP-14 (a cancer biomarker) is added to the preparation, the peptide bond is broken, separating a fragment with the dye from the gold. Without the gold to absorb the energy from the dye, the sample begins to glow, thus detecting the cancer presence.
Increasing Focus on Protein Biomarker
Protein biomarkers are gaining attention from healthcare professionals as well as patients for cancer screening. The reliability of the protein biomarker as a cancer predictor is of great significance if it is consistently expressed in cancer patients. Furthermore, the protein biomarker's widespread expression can facilitate its identification as a biomarker. Mass spectroscopy-based proteomics tools are utilized for the identification of cancer biomarkers. The increasing focus on protein biomarkers for cancer screening is expected to increase the market demand for protein biomarker-based cancer screenings.
In June 2023, Danish biomarker company Nordic Bioscience announced that its PRO-C3 biomarker assay had received a Letter of Support (LoS) from the United States Food and Drug Administration. PRO C3 is the world's first blood-based tumor fibrosis biomarker based on protein biomarkers for patients with aggressive solid tumors. Regulatory approval of promising products in the global cancer biomarkers market is anticipated to contribute to market growth in forecast years.
Government Initiatives
Government initiatives such as providing research funding, drafting supportive policies, and promoting investments for new establishments are some of the major driving forces for the market. In the global cancer biomarkers market, government organizations, associations, and agencies actively promote cancer screening and treatments through awareness initiatives, thereby fostering the market growth. The governments of several countries are funding research projects addressing cancer diagnostic techniques.
According to a press release from The White House, in March 2023, the United States government invested USD 394.5 million in three CDC programs, National Comprehensive Cancer Control Program, National Breast and Cervical Cancer Early Detection Programs, and Colorectal Cancer Control Program to address the need of screening and treatment of most prevalent type of cancer. In June 2023, as part of the Cancer Moonshot Research Initiatives, the National Institutes of Health, the FNIH, and twelve top pharmaceutical companies announced the start of the five-year, USD 220 million Partnership for Accelerating Cancer Therapies (PACT). PACT is concentrated on finding, creating, and validating strong biomarkers to promote novel treatments and therapies that engage the immune system to combat cancer. The FDA has an advising role in the partnership, which the FNIH manages.
Impact of COVID-19
COVID-19 had a notable impact on the global cancer biomarkers market. During the pandemic COVID-19 patients were of highest priority for healthcare professionals and highlighted the significance of cancer diagnostics and early detection. Cancer biomarkers, which play a pivotal role in the identification of cancer and the monitoring of treatment responses, gained increased attention as healthcare systems worldwide recognized the importance of bolstering cancer care infrastructure. Despite some disruptions in routine cancer screening programs, the pandemic accelerated the adoption of telemedicine and remote monitoring, highlighting the potential for using biomarkers in novel ways. Moreover, the urgent need for more accurate and efficient diagnostic tools spurred research and development efforts in the field of cancer biomarkers. As healthcare systems and hospitals recovered from the pandemic's disruptions, the global cancer biomarkers market saw strong growth, with an increased emphasis on early cancer detection and personalized treatment.
Key Players Landscape and Outlook
Market players are employing a range of strategies to increase their product offerings and give customers access to a wide selection of innovative products. Additionally, companies are expanding the range of diagnostic services offered to capture a bigger portion of the market. Many major industry players are using various growth techniques, like partnerships, mergers and acquisitions, development and launch of new goods, to strengthen their position in the worldwide market.
In September 2023, Ibex launched Galen Breast HER2, an AI-powered solution that helps pathologists for accurate and reproducible biomarker scoring in breast cancer patients. Ibex's Galen Breast HER2 is an AI-powered HER2 receptor scoring system that detects and quantifies the HER2 expression in breast cancer cases and scores it based on 2018 ASCO/CAP scoring guidelines. It can be utilized in screening and checking the effectiveness of treatment being provided to breast cancer patients.
1. Research Methodology
2. Project Scope & Definitions
3. Impact of COVID-19 on Global Cancer Biomarkers Market
4. Executive Summary
5. Global Cancer Biomarkers Market Outlook, 2017-2031F
5.1 Market Size & Forecast
5.1.1 By Value
5.1.2 By Volume
5.2 By Type
5.2.1 Protein Biomarkers
5.2.2 Genetic Biomarkers
5.2.2.1 Breast Cancer Genetic Biomarkers
5.2.2.2 Colorectal Cancer Genetic Biomarkers
5.2.2.3 Leukemia Genetic Biomarkers
5.2.2.4 Lung Cancer Genetic Biomarkers
5.2.2.5 Prostate Cancer Genetic Biomarkers
5.2.2.6 Other Cancer Genetic Biomarkers
5.2.3 Other Cancer Biomarkers
5.3 By Technology
5.3.1 OMICS
5.3.1.1 Proteomics
5.3.1.2 Genomics
5.3.1.2.1 Next Generation Sequencing (NGS)
5.3.1.2.2 Polymerase Chain Reaction (PCR)
5.3.1.2.3 Others
5.3.1.3 Other OMICS Technology
5.3.2 Imaging Technology
5.3.2.1 Magnetic Resonance Imaging (MRI)
5.3.2.2 Computed Tomography (CT)
5.3.2.3 Positron Emission Tomography (PET)
5.3.2.4 Mammography
5.3.2.5 Ultrasound
5.3.3 Immunoassays
5.3.4 Bioinformatics
5.3.5 Cytogenetics
5.3.5.1 In-situ Hybridization (ISH)
5.3.5.2 Other Cytogenetics Based Tests
5.4 By Cancer Type
5.4.1 Breast Cancer
5.4.2 Lung Cancer
5.4.3 Colorectal Cancer
5.4.4 Melanoma
5.4.5 Blood Cancer
5.4.6 Prostate Cancer
5.4.7 Ovarian Cancer
5.4.8 Stomach Cancer
5.4.9 Liver Cancer
5.4.10 Other Cancer
5.5 By Application
5.5.1 Diagnostics
5.5.2 Research and Development
5.5.3 Prognostics
5.5.4 Risk Assessment
5.5.5 Treatment
5.5.6 Other Applications
5.6 By End-user
5.6.1 Pharmaceutical and Biotechnological Companies
5.6.2 Diagnostic Laboratories
5.6.3 Cancer Research Institutes
5.6.4 Others
5.7 By Region
5.7.1 North America
5.7.2 Europe
5.7.3 Asia Pacific
5.7.4 South America
5.7.5 Middle East & Africa
5.8 By Company Market Share (%), 2023
6. Global Cancer Biomarkers Market Outlook, 2017-2031F
6.1. North America*
6.1.1. Market Size & Forecast
6.1.1.1. By Value
6.1.1.2. By Volume
6.1.2. By Type
6.1.2.1. Protein Biomarkers
6.1.2.2. Genetic Biomarkers
6.1.2.2.1. Breast Cancer Genetic Biomarkers
6.1.2.2.2. Colorectal Cancer Genetic Biomarkers
6.1.2.2.3. Leukemia Genetic Biomarkers
6.1.2.2.4. Lung Cancer Genetic Biomarkers
6.1.2.2.5. Prostate Cancer Genetic Biomarkers
6.1.2.2.6. Other Cancer Genetic Biomarkers
6.1.2.3. Other Cancer Biomarkers
6.1.3. By Technology
6.1.3.1. OMICS
6.1.3.1.1. Proteomics
6.1.3.1.2. Genomics
6.1.3.1.2.1. Next Generation Sequencing (NGS)
6.1.3.1.2.2. Polymerase Chain Reaction (PCR)
6.1.3.1.2.3. Others
6.1.3.1.3. Other OMICS Technology
6.1.3.2. Imaging Technology
6.1.3.2.1. Magnetic Resonance Imaging (MRI)
6.1.3.2.2. Computed Tomography (CT)
6.1.3.2.3. Positron Emission Tomography (PET)
6.1.3.2.4. Mammography
6.1.3.2.5. Ultrasound
6.1.3.3. Immunoassays
6.1.3.4. Bioinformatics
6.1.3.5. Cytogenetics
6.1.3.5.1. In-situ Hybridization (ISH)
6.1.3.5.2. Other Cytogenetics Based Tests
6.1.4. By Cancer Type
6.1.4.1. Breast Cancer
6.1.4.2. Lung Cancer
6.1.4.3. Colorectal Cancer
6.1.4.4. Melanoma
6.1.4.5. Blood Cancer
6.1.4.6. Prostate Cancer
6.1.4.7. Ovarian Cancer
6.1.4.8. Stomach Cancer
6.1.4.9. Liver Cancer
6.1.4.10. Other Cancer
6.1.5. By Application
6.1.5.1. Diagnostics
6.1.5.2. Research and Development
6.1.5.3. Prognostics
6.1.5.4. Risk Assessment
6.1.5.5. Treatment
6.1.5.6. Other Applications
6.1.6. By End-user
6.1.6.1. Hospitals
6.1.6.2. Pharmaceutical and Biotechnological Companies
6.1.6.3. Diagnostic Laboratories
6.1.6.4. Cancer Research Institutes
6.1.6.5. Others
6.1.7. United States*
6.1.7.1. Market Size & Forecast
6.1.7.1.1. By Value
6.1.7.1.2. By Volume
6.1.7.2. By Type
6.1.7.2.1. Protein Biomarkers
6.1.7.2.2. Genetic Biomarkers
6.1.7.2.2.1. Breast Cancer Genetic Biomarkers
6.1.7.2.2.2. Colorectal Cancer Genetic Biomarkers
6.1.7.2.2.3. Leukemia Genetic Biomarkers
6.1.7.2.2.4. Lung Cancer Genetic Biomarkers
6.1.7.2.2.5. Prostate Cancer Genetic Biomarkers
6.1.7.2.2.6. Other Cancer Genetic Biomarkers
6.1.7.2.3. Other Cancer Biomarkers
6.1.7.3. By Technology
6.1.7.3.1. OMICS
6.1.7.3.1.1. Proteomics
6.1.7.3.1.2. Genomics
6.1.7.3.1.2.1. Next Generation Sequencing (NGS)
6.1.7.3.1.2.2. Polymerase Chain Reaction (PCR)
6.1.7.3.1.2.3. Others
6.1.7.3.1.3. Other OMICS Technology
6.1.7.3.2. Imaging Technology
6.1.7.3.2.1. Magnetic Resonance Imaging (MRI)
6.1.7.3.2.2. Computed Tomography (CT)
6.1.7.3.2.3. Positron Emission Tomography (PET)
6.1.7.3.2.4. Mammography
6.1.7.3.2.5. Ultrasound
6.1.7.3.3. Immunoassays
6.1.7.3.4. Bioinformatics
6.1.7.3.5. Cytogenetics
6.1.7.3.5.1. In-situ Hybridization (ISH)
6.1.7.3.5.2. Other Cytogenetics Based Tests
6.1.7.4. By Cancer Type
6.1.7.4.1. Breast Cancer
6.1.7.4.2. Lung Cancer
6.1.7.4.3. Colorectal Cancer
6.1.7.4.4. Melanoma
6.1.7.4.5. Blood Cancer
6.1.7.4.6. Prostate Cancer
6.1.7.4.7. Ovarian Cancer
6.1.7.4.8. Stomach Cancer
6.1.7.4.9. Liver Cancer
6.1.7.4.10. Other Cancer
6.1.7.5. By Application
6.1.7.5.1. Diagnostics
6.1.7.5.2. Research and Development
6.1.7.5.3. Prognostics
6.1.7.5.4. Risk Assessment
6.1.7.5.5. Treatment
6.1.7.5.6. Other Applications
6.1.7.6. By End-user
6.1.7.7. Hospitals
6.1.7.8. Pharmaceutical and Biotechnological Companies
6.1.7.9. Diagnostic Laboratories
6.1.7.10. Cancer Research Institutes
6.1.7.11. Others
6.1.8. Canada
6.1.9. Mexico
*All segments will be provided for all regions and countries covered
6.2. Europe
6.2.1. Germany
6.2.2. France
6.2.3. Italy
6.2.4. United Kingdom
6.2.5. Russia
6.2.6. Netherlands
6.2.7. Spain
6.2.8. Turkey
6.2.9. Poland
6.3. South America
6.3.1. Brazil
6.3.2. Argentina
6.4. Asia-Pacific
6.4.1. India
6.4.2. China
6.4.3. Japan
6.4.4. Australia
6.4.5. Vietnam
6.4.6. South Korea
6.4.7. Indonesia
6.4.8. Philippines
6.5. Middle East & Africa
6.5.1. Saudi Arabia
6.5.2. UAE
6.5.3. South Africa
7. Market Mapping, 2023
7.1. By Type
7.2. By Technology
7.3. By Cancer Type
7.4. By Application
7.5. By End-user
7.6. By Region
8. Macro Environment and Industry Structure
8.1. Supply Demand Analysis
8.2. Import Export Analysis - Volume and Value
8.3. Supply/Value Chain Analysis
8.4. PESTEL Analysis
8.4.1. Political Factors
8.4.2. Economic System
8.4.3. Social Implications
8.4.4. Technological Advancements
8.4.5. Environmental Impacts
8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
8.5. Porter's Five Forces Analysis
8.5.1. Supplier Power
8.5.2. Buyer Power
8.5.3. Substitution Threat
8.5.4. Threat from New Entrant
8.5.5. Competitive Rivalry
9. Market Dynamics
9.1. Growth Drivers
9.2. Growth Inhibitors (Challenges, Restraints)
10. Regulatory Framework and Innovation
10.1. Clinical Trials
10.2. Patent Landscape
10.3. Regulatory Approvals
10.4. Innovations/Emerging Technologies
11. Key Players Landscape
11.1. Competition Matrix of Top Five Market Leaders
11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
11.4. SWOT Analysis (For Five Market Players)
11.5. Patent Analysis (If Applicable)
12. Pricing Analysis
13. Case Studies
14. Key Players Outlook
14.1. Abbott
14.1.1. Company Details
14.1.2. Key Management Personnel
14.1.3. Products & Services
14.1.4. Financials (As reported)
14.1.5. Key Market Focus & Geographical Presence
14.1.6. Recent Developments
14.2. Thermo Fisher Scientific Inc.
14.3. Illumina, Inc.
14.4. QIAGEN
14.5. F. Hoffmann-La Roche Ltd
14.6. Agilent Technologies, Inc.
14.7. Quest Diagnostics Incorporated
14.8. Merck KGaA
14.9. Hologic, Inc.
14.10. Bio-Rad Laboratories
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work
15. Strategic Recommendations
16. About Us & Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security